After a monster year 2021, during which CDMO Recipharm extended its footprint around the world in places where the manufacturing presence is less, it is expanding its footprint in a European country where it is already established: Portugal.
The Swedish company announced the acquisition of GenIbet, a CDMO based in Oeiras, Portugal, which was created from an iBET laboratory – Instituto de Biologia Experimental e Tecnológica – in 2016. The move will help Recipharm expand its capabilities in organic products and to benefit from the expertise of GenIbet. experience with viral vectors and vaccines as it seeks to focus on manufacturing new advanced therapy drugs. It will inherit the 70 employees of GenIbet on the neighboring site just 11 km from Recipharm’s facilities in Lisbon.
GenIbet made headlines last year when it revealed it was working with Moderna to produce some of the first batches of mRNA for Moderna between 2015 and 2019. It was the only manufacturer in Portugal to exploit these rights bragging rights and received a thank you from Moderna CEO Stephane. Bank.
“Moderna is very grateful to GenIbet Biopharmaceuticals,” he said in 2020. “They partnered to take Moderna’s first-ever mRNA vaccine into the clinic in late 2015. The GenIbet team provided Moderna with a GMP product from high quality and we are grateful for his work.
Although the work was not directly related to Covid-19 research, studying the mRNA technology helped Moderna learn more about the technology that was ultimately used in vaccines.
GenIbet was separated from iBet when its need for proper manufacturing arose. There was demand to move its work to clinical trials, CEO Raquel Fortunato told SAPO24 News in Portugal, and iBet lacked clean rooms and other cGMP requirements. Now the company is focused on offering manufacturing solutions where no route has already been established.
“We have enjoyed great success at GenIbet, and now is a fantastic time to join Recipharm to share our expertise and broad service offering,” Fortunato said in a statement.
In a statement, Recipharm CEO Marc Funk said:
We are delighted to welcome GenIbet and its talented team of experts. GenIbet is a leading player in its field, so we are proud to bring it together under the Recipharm umbrella and leverage its broad offering of new modalities and incredible scientific expertise. This acquisition is an important step for us in growing our biologics business. We look forward to working closely with the GenIbet team, making connections within the wider Recipharm organization to make this venture a huge success.
In January, Recipharm sold its manufacturing site in Fontaine-lès-Dijon, France, to a newly created CDMO Astrea Pharma and Aesica Pharmaceuticals and the UK active pharmaceutical ingredient manufacturing site to Pharmaron. This deal provided the company with liquidity to help propel it into the top five of global CDMOs.
In July 2021, the company announced the construction of a new fill-finish facility in Uttarakhand, India, near Dehradun, as part of a partnership with the Sobti family that began in 2019.
It is also building a fill-finish plant in Morocco, largely thanks to a $500 million investment from the government over the next five years. This site will focus on manufacturing vaccines for Africa.